Klinik Kullanım İçin Mezenkimal Kök Hücrelerin Hazırlanması

Year 2019, Volume: 5 Issue: 2, 169 - 175, 01.01.2019

Zeynep Burçin Gönen Nur Seda Şahin

Abstract

Mezenkimal kök hücreler MKH kendini yenileme potansiyeli olan, osteoblast, kondrosit ve adiposit gibi özelleşmiş hücrelere farklılaşabilme yeteneğine sahip, erişkin, multipotent hücrelerdir. Klinikte kullanılmaları için özel üretim koşulları gerekmektedir. GMP Good Manufacturing Practice- İyi Üretim Uygulamaları şartlarında hücre üretimi, temel kök hücre bilimlerinden klinik araştırmalara ve uygulamalara translasyon için yüksek bir kalite güvence sistemi sağlar. Üretim protokolünde kullanılan enzim içeriği ve konsantrasyonu, parçalanma süresi, santrifüj hız farklılıkları, filtre boyutu gibi değişkenler, MKH eldesindeki farklılıkları oluşturur. Uygun üretim, doz ve uygulama yolu standardize edilerek hastada en başarılı tedavi sonucuna ulaşılır. Derlemede, MKH' lerin özelliklerini ve klinikte kullanımlarına özgü olarak nasıl hazırlandıklarını ve hazırlanma esnasındaki değişkenlerin hücre üzerine etkilerini açıklanması amaçlanmıştır

Keywords

Mezenkimal kök hücre, Translasyonel tıp, GMP

Mesenchymal Stem Cell Production for Clinical Usage

Abstract

Mesenchymal stem cells MSC are multipotent cells that can differentiate into specialized cells such as osteoblasts, chondrocytes and adipocytes, and have the ability for self-renewal. However, special production conditions are required for clinical usage. GMP Good Manufacturing Practice Laboratory conditions may provide a high quality control system in translational medicine from basic stem cell research to clinical trials. The content and concentration of the enzyme, digestion period, the speed of the centrifuge and filter size may be among the variables that affect the characteristics of MSCs. The production methods, application and dose of MSCs for certain therapies should therefore be standardized according to the best clinical treatment available for the patient. The aim of this review is to explain the characteristics of MSCs, the special production methods for their use in clinical practice, and their effects on various cells

Keywords

Mesenchymal stem cell, Translational medicine, GMP

References

• 1. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8:315-17.
• 2. Pendleton C, Li Q, Chesler DA, Yuan K, GuerreroCazares H, Quinones-Hinojosa A. Mesenchymal stem cells derived from adipose tissue vs bone marrow: In vitro comparison of their tropism towards gliomas. PLoS One 2013;8:581-98.
• 3. Thirumala S, Goebel WS, Woods EJ. Clinical grade adult stem cell banking. Organogenesis 2009;5:143-54.
• 4. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-7.
• 5. Li H, Ghazanfari R, Zacharaki D, Lim HC, Scheding S. Isolation and characterization of primary bone marrow mesenchymal stromal cells. Ann NY Acad Sci 2016; 1370:109-18.
• 6. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: Implications for cellbased therapies. Tissue Eng 2001;7(2):211-28.
• 7. Kolaparthy LK, Sanivarapu S, Moogla S, Kutcham RS. Adipose tissue-adequate, accessible regenerative material. Int J Stem Cells 2015;8:121-7.
• 8. Bersenev A. Cell therapy clinical trials-2014 report. Cell Trials Blog, 2015.
• 9. Fellows CR, Matta C, Zakany R, Khan İM, Mobasheri A. Adipose, bone marrow and synovial joint-derived mesenchymal stem cells for cartilage repair. Front Genet 2016;7:213.
• 10. Tatullo M, Codispoti B, Pacifici A, Palmieri F, Marrelli M, Pacifici L, Paduano F. Potential use of human periapical cyst-mesenchymal stem cells (hPCy-MSCs) as a novel stem cell source for regenerative medicine applications. Front Cell Dev Biol 2017;5:103.
• 11. Mobasheri A, Kalamegam G, Musumeci G, Batt ME. Maturitas chondrocyte and mesenchymal stem cell-based therapies for cartilage repair in osteoarthritis and related orthopaedic conditions 2014; 78(3):188-98.
• 12. Sellam J, Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatology 2010; 6(11):625-35.
• 13. Gronthos S, Mankani M, Brahim J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA 2000;97(25):13625 30.
• 14. Alsalameh S, Amin R, Gemba T, Lotz M. Identification of mesenchymal progenitor cells in normal and osteoarthritic human articular cartilage. Rheum A 2004; 50 (5):1522-32.
• 15. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L, Norotte C, Teng PN, Traas J, Schugar R, Deasy BM, Badylak S, Buhring HJ, Giacobino JP, Lazzari L, Huard J, Péault B.A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008;3(3):301-13.
• 16. Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, Eckstein V, Ansorge W. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005;33:1402-16.
• 17. Ozbey O, Sahin Z, Acar N, Ozcelik FT, Ozenci AM, Koksoy S, Ustunel I. Characterization of colony-forming cells in adult human articular cartilage. Acta Histochem 2014;116(5):763-70.
• 18. Ustunel I, Ozenci AM, Sahin Z, Ozbey O, Acar N, Tanriover G, Celik-Ozenci C, Demir R. The immunohistochemical localization of notch receptors and ligands in human articular cartilage, chondroprogenitor culture and ultrastructural characteristics of these progenitor cells. Acta Histochem 2008;110(5):397-07.
• 19. Baglioni S, Francalanci M, Squecco R, Lombardi A, Cantini G, Angeli R, Gelmini S, Guasti D, Benvenuti S, Annunziato F. Characterization of human adult stemcell populations isolated from visceral and subcutaneous adipose tissue. FASEB J 2009; 23:3494-05.
• 20. Türkiye İlaç ve Tıbbi Cihaz Kurumundan: İnsan Doku ve Hücre Ürünlerinin Ruhsatlandırılması ve bu Ürünlerin Üretim, İthalat, İhracat, Depolama ve Dağıtım Faaliyetlerini Yürüten Merkezler hakkında Tebliğ. 4 Nisan 2014 Resmi gazete sayı: 28962.
• 21. Türkiye İlaç ve Tıbbi Cihaz Kurumundan: İnsan Doku ve Hücreleri İle Bunlarla İlgili Merkezlerin Kalite ve Güvenliği Hakkında Yönetmelik 27 Ekim 2010 Resmi Gazete sayı: 27742.
• 22. Shi YY, Nacamuli RP, Salim A, Longaker MT. The osteogenic potential of adipose derived mesenchymal cells is maintained with aging. Plast Reconstr Surg 2005; 116:1686-96.
• 23. Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 2007;25:1384-92.
• 24. Rebelatto CK, Aguiar AM, Moretão MP, Senegaglia AC, Hansen P, Barchiki F, Oliveira J, Martins J, Kuligovski C, Mansur F, Christofis A, Amaral VF, Brofman PS, Goldenberg S, Nakao LS, Correa A. Dissimilar differentiation of mesenchymal stem cells from bone marrow, umbilical cord blood, and adipose tissue. Exp Biol Med (Maywood) 2008;233:901-13.
• 25. Baer PC, Geiger H. Adipose-derived mesenchymal stromal/stem cells: tissue localization, characterization, and heterogeneity. Stem Cells Int 2012;812693.
• 26. Zhu Y, Liu T, Song K, Fan X, Ma X, Cui Z. Adiposederived stem cell: A better stem cell than BMSC. Cell Biochem Funct 2008;26:664-75.
• 27. Smith RJ,Pfeifer K, Petry F,Powell N,Delzeit J,Weiss M. Standardizing umbilical cord mesenchymal stromal cells for translation to clinical use: Selection of GMP-compliant medium and a simplified isolation method. Stem Cells Int 2016; 6810980.
• 28. Atala A. Methods of Tissue Engineering. Houston, Texas: Gulf Professional Publishing; 2002.
• 29. Salehinejad P, Alitheen NB, Ali AM, Omar AR, Mohit M, Janzamin E, Samani FS, Torshizi Z, NematollahiMahani SN. Comparison of different methods for the isolation of mesenchymal stem cells from human umbilical cord Wharton’s jelly In Vitro Cell. Dev Biol Anim 2012; 48:75-83.
• 30. Yoon JH, Roh EY, Shin S, Jung NH, Song EY, Chang JY, Kim BJ, Jeon HW. Comparison of explant-derived and enzymatic digestion-derived MSCs and the growth factors from Wharton’s jelly. Biomed Res Int 2013;428726.
• 31. Hilkens P, Gervois P, Fanton Y, Vanormelingen J, Martens W, Struys T, Politis C, Lambrichts I, Bronckaers A. Effect of isolation methodology on stem cell properties and multilineage differentiation potential of human dental pulp stem cells. Cell Tissue Res 2013; 353:65-78.
• 32. Hendijani F. Explant culture: An advantageous method for isolation of mesenchymal stem cells from human tissues. Cell Prolif 2017;50:12334.
• 33. Hynes RO. The extracellular matrix: Not just pretty fibrils. Science 2009;326:1216-19.
• 34. Raposio E, Simonacci F, Perrotta RE. Adipose-derived stem cells: Comparison between two methods of isolation for clinical applications. Ann Med Surg (Lond) 2017;20: 87-91.
• 35. Lazzina R, Mariotti A, Procoli A, Fioravanti D, Iudicone P, Scambia G, Pierelli L, Bonanno G. A new standardized clinical-grade protocol for banking human umbilical cord tissue cells. Transplantation and Cellular Engineerıng 2015;55(12):2864-73.
• 36. Jurgens WJ, Oedayrajsingh-Varma MJ, Helder MN, Zandiehdoulabi B, Schouten TE, Kuik DJ, Ritt MJ, van Milligen FJ. Effect of tissue-harvesting site on yield of stem cells derived from adipose tissue: Implications for cellbased therapies. Cell Tissue Res 2008;332:415-26.
• 37. Heiskanen A, Satomaa T, Tiitinen S, Laitinen A, Mannelin S, Impola U, Mikkola M, Olsson C, MillerPodraza H, Blomqvist M, Olonen A, Salo H, Lehenkari P, Tuuri T, Otonkoski T, Natunen J, Saarinen J, Laine J. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 2007;25:197-202.
• 38. Sundin M, Ringd O, Sundberg B, Nava S, Geotherstreom C, Le Blanc K. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 2007; 92:1208-15.
• 39. Dimarakis I, Levicar N. Cell culture medium composition and translational adult bone marrow-derived stem cell research. Stem Cells 2006;24:1407-08.
• 40. Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, Lataillade JJ. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiology 2005; 205(2):228-36.
• 41. Müller I, Kordowich S, Holzwarth C, Spano C, Isensee G, Staiber A, Viebahn S, Gieseke F, Langer H, Gawaz MP, Horwitz EM, Conte P, Handgretinger R, Dominici M. Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 2006;8(5):437-44.
• 42. Bartmann C, Rohde E, Schallmoser K, Purstner P, Lanzer G, Linkesch W, Strunk D. Two steps to functional mesenchymal stromal cells for clinical application. Transfusion 2007;47(8):1426-35.
• 43. Bieback K, Hecker A, Kocaomer A, Lannert H, Schallmoser K, Strunk D, Klüter H. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009; 27(9):2331-41.
• 44. Fekete N, Rojewski MT, Furst D, Kreja L, Ignatius A, Dausend J, Schrezenmeier H. GMP-compliant isolation and large-scale expansion of bone marrow-derived MSC. PLoS One 2012;7(8)43255.
• 45. Bernardo ME, Avanzini MA, Perotti C. Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: Further insights in the search for a fetal calf serum substitute. J Cell Physiol 2007;211:121-30.
• 46. Sotiropoulou PA, Perez SA, Salagianni M. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 2006;24:462-71.
• 47. Both SK, Muijsenberg AJ, Blitterswijk CA. A rapid and efficient method for expansion of human mesenchymal stem cells. Tissue Eng 2007;13:3-9.
• 48. Tsutsumi S, Shimazu A, Miyazaki K. Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. Biochem Biophys Res Commun 2001;288:413-19.
• 49. Solchaga LA, Penick K, Porter JD. FGF-2 enhances the mitotic and chondrogenic potentials of human adult bone marrow-derived mesenchymal stem cells. J Cell Physiol 2005;203:398-409.
• 50. Martin I, Muraglia A, Campanile G. Fibroblast growth factor-2 supports ex vivo expansion and maintenance of osteogenic precursors from human bone marrow. Endocrinology 1997;138:4456-62.
• 51. Bianchi G, Banfi A, Mastrogiacomo M. Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Exp Cell Res 2003;287:98-105.
• 52. Gharibi B, Hughes F. Effects of medium supplements on proliferation, differentiation potential, and in vitro expansion of mesenchymal stem cells. Stem Cells Translasyonel Medicine 2012;1(11):771-82.
• 53. Sanchez-Guijo F, Caballero-Velazquez T, Lopez-Villar O, Redondo A, Parody R, Martinez C, Olavarría E, Andreu E, Prósper F, Díez-Campelo M, Regidor C, Villaron E, López-Corral L, Caballero D, Cañizo MC, Pérez-Simon JA. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versushost disease. Biol Blood Marrow Transplant 2014; 20(10):1580-5.
• 54. Astori G, Amati E, Bambi F, Bernardi M, Chieregato K, Schäfer R, Sella S, Rodeghiero F. Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: Present and future. Stem Cell Res Ther 2016;7:93.
• 55. Chase LG, Lakshmipathy U, Solchaga LA, Rao MS, Vemuri MC. A novel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell Res Ther 2010;21-8.
• 56. Hudson JE, Mills RJ, Frith JE, Brooke G, JaramilloFerrada P, Wolvetang EJ, Cooper-White JJ. A defined medium and substrate for expansion of human mesenchymal stromal cell progenitors that enriches for osteo- and chondrogenic precursors. Stem Cells Dev 2011;20:77-87.
• 57. Song L, Webb NE, Song Y, Tuan RS. Identification and functional analysis of candidate genes regulating mesenchymal stem cell self-renewal and multipotency. Stem Cells 2006;24:1707-18.
• 58. Neth P, Ciccarella M, Egea V, Hoelters J, Jochum M, Ries C. Wnt signaling regulates the invasion capacity of human mesenchymal stem cells. Stem Cells 2006;24:1892-103.
• 59. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide cell. Stem Cell 2008;2:141- 50.
• 60. Marquez-Curtis LA, Janowska-Wieczorek A, McGann LE, Elliott JA. Mesenchymal stromal cells derived from various tissues: Biological, clinical and cryopreservation aspects. Cryobiology 2015;71(2):181-97.
• 61. Roy S, Arora S, Kumari P, Ta M. A simple and serumfree protocol for cryopreservation of human umbilical cord as source of Wharton’s jelly mesenchymal stem cell. Cryobiology 2014;68(3):467-72.
• 62. Yuan Z, Lourenco S, Sage EK, Kolluri K, Lowdell M, Janes SM. Cryopreservation of human mesenchymal stromal cells expressing TRAIL for human anti-cancer therapy. Cytotherapy 2016;18(7):860-9.
• 63. Miyamoto Y, Oishi K, Yukawa H, Noguchi H, Sasaki M, Iwata H, Hayashi S. Cryopreservation of human adipose tissue-derived stem/progenitor cells using the silk protein sericin. Cell Transplant 2012;21(2-3):617-22.
• 64. Al-Saqi SH, Saliem M, Quezada HC, Ekblad A, Jonasson AF, Hovatta O, Götherström C. Defined serum- and xeno-free cryopreservation of mesenchymal stem cells. Cell Tissue Bank 2015;16(2):181-93.
• 65. Chatzistamatiou T, Papassavas A, Michalopoulos E, Gamaloutsos C, Mallis P, Gontika I, Panagouli E, Koussoulakos S, Stavropoulos-Giokas C. Optimizing isolation culture and freezing methods to preserve Wharton’s jelly’s mesenchymal stem cell (MSC) properties: an MSC banking protocol validation for the Hellenic Cord Blood Bank. Transplantation and Cellular Engineering 2014;54(12):3108-20.
• 66. Dragoo JL, Choi JY, Lieberman JR, Huang J, Zuk PA, Zhang J, Hedrick MH, Benhaim P. Bone induction by BMP-2 transduced stem cells derived from human fat. J Orthop Res 2003;21:622-9.
• 67. Galie M, Pignatti M, Scambi I, Sbarbati A, Rigotti G. Comparison of different centrifugation protocols for the best yield of adipose-derived stromal cells from lipoaspirates. Plast Reconstr Surg 2008;122:233-4.
• 68. Kim WS, Park BS, Sung JH. Protective role of adiposederived stem cells and their soluble factors in photoaging. Arch Dermatol Res 2009;301:329-36